Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile duct. The bile duct is located in the liver and transports bile from the liver to the small intestine. Bile helps to break down fats in the foods eaten. It is a rare cancer, but has high mortality rates as it is usually diagnosed at an advanced stage. Common symptoms include jaundice, itching, weight loss and abdominal pain. Treatment options for cholangiocarcinoma include surgery, radiation therapy, chemotherapy, liver transplantation, stent placement and photodynamic therapy.
The global cholangiocarcinoma market is estimated to be valued at US$ 7,275.7 Mn or US$ 7.3 Bn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics: The cholangiocarcinoma market is expected to witness high growth owing to the increasing incidence rates of bile duct cancer globally. According to recent studies, the global incidence rates of cholangiocarcinoma have increased in the past few decades, mainly attributed to risk factors such as liver flukes, primary sclerosing cholangitis, Hepatitis C infection and obesity. For instance, as per the United States National Cancer Institute, around 8,000 to 12,000 new cases of cholangiocarcinoma are diagnosed each year in the US. Furthermore, rising obese population worldwide has also led to rising cases of non-alcoholic fatty liver disease which is a risk factor for cholangiocarcinoma. This increasing patient pool is expected to drive the demand for diagnostic procedures, treatment therapies and devices used in cholangiocarcinoma management over the forecast period.
SWOT Analysis
Strength: Cholangiocarcinoma treatments include chemotherapy, radiation therapy, and surgery which have shown promising outcomes in clinical trials to extend survival and improve quality of life for patients. Several new drugs are in late stage clinical trials with the potential to increase effectiveness of existing therapies. Government and nonprofit funding for research has led to advances in early detection and personalized treatment options.
Weakness: Cholangiocarcinoma is a rare form of cancer making research funding and drug development more challenging. Diagnosis can be difficult as symptoms are often vague in early stages. Many patients are not eligible for curative intent surgery due to late stage at detection.
Opportunity: growth of the biologics and targeted therapy market provides opportunities to develop new combination treatments. Increasing awareness through patient advocacy groups may result in earlier diagnosis and improved outcomes. Development of novel biomarkers can enable earlier screening and precision medicine approaches.
Threats: stringent regulatory processes for approval of new oncology drugs increases costs and timelines of drug development. Intellectual property litigation between drug manufacturers poses risks. Potential side effects and resistance limit long term effectiveness of current therapies.
Key Takeaways
The global Cholangiocarcinoma market is expected to witness high growth over the forecast period of 2023 to 2030 supported by a rising CAGR of 7.6%.
Regional analysis shows Asia Pacific as the fastest growing region due to large patient populations and improving access to care in China, India, and Japan. North America currently dominates the market due to strong research funding and payer coverage of new therapeutics in the United States.
Key players operating in the Cholangiocarcinoma market are Johnson & Johnson Services, Inc., Cooper Companies Inc., Lifecell Corporation (Allergan Plc), W. L. Gore & Associates, Inc., Maquet Holding B.V. & Co. KG, Becton, Dickinson and Company, Medtronic Plc, Cook Medical Inc., Baxter International Inc., and B. Braun Melsungen AG. These global companies provide a variety of treatment options including chemotherapy, radiation therapy, cancer drugs, medical devices and surgical instruments. Market consolidation is expected through mergers and acquisitions to gain access to new therapies and regions.
The Spirulina Market is expected to grow at a CAGR of 10.3% from 2020-2030, according to a new research report by Next Move Strategy ConsultingSpirulina is a blue green algae with high nutrient content, usually consumed by human & animals.
It is also used as a complementary diet ingredient in aquaculture & poultry feeds owing to the presence of high protein & vitamin content.According to the report, growth in health consciousness among people and the rising demand for dietary supplements are major factors driving the spirulina market growth.
Additionally, high penetration of spirulina in industries such as cosmetics and pharmaceutical owing to the advantageous properties such as anti-aging, anti-wrinkles and othersare bringing changes in market tends.However, low stability & poor sustainability of spirulina derived colours is expected to restrict the market growth.Moreover, growth in research & development activities followed by untapped market opportunities in developing economies are anticipated to provide numerous opportunities to the market players in the coming few years.On the basis of type, spirulina market share is segmented into Arthrospira Platensis and Arthrospira Maxima.
Arthrospira Maxima dominates the global Spirulina market and will be the dominant throughout the forecasted period.On the basis of application, the Spirulina market is categorised into Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others.Food & Beverages segment is likely to develop significantly over the period of time owing to fast growing food & beverage industry.On the basis of drug formulation, the spirulina market is bifurcated into Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent.
Powder segment is expected to account for the major market share & dominate the market growth over the forecast period.North America dominates the spirulina market in terms of market size over the forecast period, owing to rising health consciousness among people.
Hansen Holding A/S, Algenol Biofuels Inc., Dongtai City Spirulina Bio-engineering Co., Ltd., Prolgae, Parry Neutraceuticals, Sensient Technologies Corporation, DDW Inc., Algatec and Naturex S.A.Browse key industry insights from the report, “Spirulina Market Size By Type (ArthrospiraPlatensis and Arthrospira Maxima) By Application (Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others), By Drug Formulation (Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent)Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, Indonesia, Malaysia, South Korea, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Kuwait), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2030” in detail along with the table of contents:Key Insights from the Spirulina Market Report:Asia Pacific is the fastest growing region in Spirulina market owing to the rising demand of spirulina from various industries such as cosmetics, food , healthcare and others and government initiatives to promote local spirulina production.The Food & Beverages segment dominates the market in terms of application and is expected to grow at a significant CAGR to maintain the lead till 2030.Some of the major players in the market are DIC Corporation, Cyanotech Corporation, Chr.
Jul 18, 2019 (AB Digital via COMTEX) -- The Bile Duct Cancer Market Size To Project Lucrative CAGR of 9.2% By 2023 in the forecast period.
Intensifying number of bile duct cancer cases being diagnosed globally have fortified the need for cutting-edge solutions in terms of procedure and medicines to treat the condition.
Market reports associated with the healthcare sector made accessible by Market Research Future along with published reports on other sectors have been lately put out along with a report on this industry.
Bile Duct Cancer Market Segmental Analysis
The market for bile duct cancer is segmented based on
By diagnosis the bile duct cancer market is segmented into
